Pacira halts DepoCyt production over manufacturing issue

Pacira Pharmaceuticals (NSDQ:PCRX) said late last month that it plans to stop producing its liposomal chemotherapeutic due to “persistent technical issues specific to the DepoCyt(e) manufacturing process.”

In a regulatory note filed to the SEC, the N.J.-based company said it expects a charge of $5 million thanks to the discontinuation, including $500,000 related to employee lay-offs.

Get the full story at our sister site, Drug Delivery Business News.

The post Pacira halts DepoCyt production over manufacturing issue appeared first on MassDevice.

from MassDevice http://ift.tt/2tUnSMf